Please provide your email address to receive an email when new articles are posted on . MindMed will use Catalent’s Zydis orally disintegrating tablet technology for the development of MM-120, an ...

Study Confirms MDMA Is Stable on Zydis(R) ODT and Suitable for Pre-Gastric Absorption Toronto, Ontario--(Newsfile Corp. - October 4, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce that it has signed an agreement with Catalent, Inc. (Catalent) (NYSE: CTLT), to develop innovative ...

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an ...

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to ...

The agreement will focus on investigating a market-ready proprietary formulation and optimized delivery route for MDMA using Catalent's proprietary Zydis ® orally disintegrating tablet (ODT) ...

Catalent, Inc. CTLT recently executed a development and license agreement with Ethicann Pharmaceuticals Inc. to develop Ethicann’s clinical drug pipeline using its proprietary Zydis orally ...

Under the terms of the licensing agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead product candidate MM-120 (lysergide D-tartrate), which is ...